This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, W.-Y. Articles by Hayes, R. B. Search for Related Content PubMed PubMed Citation Articles by Huang, W.-Y. Articles by Hayes, R. B.

Microsomal Epoxide Hydrolase Polymorphisms and Risk for Advanced Colorectal Adenoma

¹ Division of Cancer Epidemiology and Genetics, ² Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland; ³ Laboratory of Genomic Diversity, National Cancer Institute-Frederick, Frederick, Maryland; ⁴ Core Genotyping Facility, Advanced Technology Center, National Cancer Institute-Frederick, Gaithersburg, Maryland; ⁵ Division of Gastroenterology, University of Pittsburgh, Pittsburgh, Pennsylvania; and ⁶ Josephine Ford Cancer Center, Henry Ford Health Sciences Center, Detroit, Michigan

Requests for reprints: Wen-Yi Huang, Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS 8113, MSC 7240, Bethesda, MD 20892. Phone: 301-435-4710; Fax: 301-402-1819. E-mail: huangw{at}mail.nih.gov

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cigarette smoking is a risk factor for colorectal adenoma, a precursor of colorectal cancer. Microsomal epoxide hydrolase (EPHX1) metabolizes polycyclic aromatic hydrocarbons, carcinogens found in cigarette smoke. Nonsynonymous variants of EPHX1 at Tyr₁₁₃His (exon 3) and His₁₃₉Arg (exon 4) are associated, respectively, with low (₁₁₃His) and high (₁₃₉Arg) predicted activity. Among participants randomized to the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we evaluated risks for advanced adenoma in relation to cigarette use and these two EPHX1 variants. We compared 772 cases with advanced adenoma (adenoma 1 cm or containing high-grade dysplasia or villous, including tubulovillous, elements) of the distal colon (left-sided, descending colon and sigmoid or rectum) to 777 gender- and age-matched controls who were screen-negative for left-sided adenoma. Compared to those with homozygous genotypes predicting low EPHX1 activity, advanced adenoma risks tended to be elevated for carriers of ₁₁₃TyrTyr [odds ratios (OR), 1.5; 95% confidence intervals (CI), 1.0-2.2] and ₁₃₉ArgArg (OR, 1.4; 95% CI, 0.8-2.5) and for subjects who carried a greater number of the alleles (₁₁₃Tyr or ₁₃₉Arg) associated with high predicted enzymatic activity (P_trend = 0.03). The increased risk associated with the increasing number of putative high-activity alleles was most apparent among current and recent (quit <10 years) cigarette smokers (P_trend = 0.02). In conclusion, EPHX1 variants at codon 113 and 139 associated with high predicted enzymatic activity appear to increase risk for colorectal adenoma, particularly among recent and current smokers.

Key Words: Epoxide hydrolase • Colorectal adenoma • Epidemiology • Smoking • Polycyclic aromatic hydrocarbons (PAH)

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Colorectal carcinogenesis involves both environmental and genetic factors (1, 2). Colorectal adenomas are cancer precursors (3). Identifying the determinants of these premalignant lesions is important for understanding the causes of colorectal cancer. We (4) and others (5) have related cigarette use, and particularly current and recent use, to increased risk for colorectal adenoma.

Microsomal epoxide hydrolase (EPHX1) metabolizes a broad array of epoxide substrates, including polycyclic aromatic hydrocarbons (PAH), carcinogens found in cigarette smoke (6). EPHX1 converts the tobacco combustion product benzo(a)pyrene-derived benzo(a)pyrene 7,8-epoxide to the less toxic transdihydrodiol derivative, benzo(a)pyrene 7,8 diol (7). Although the enzyme activity of EPHX1 is detoxifying with respect to the epoxide, the diol subsequently serves as the primary substrate for cytochrome P450 conversion to the highly reactive benzo(a)pyrene 7,8 dihydrodiol 9,10-epoxide (BPDE, ref. 7). BPDE forms adducts in DNA hotspots and is considered a major tobacco-derived benzo(a) pyrene carcinogen (8). PAH are also found in foods cooked at high temperatures, although typically resulting in lower doses than that derived from tobacco smoke (9).

The several-fold variation in substrate-specific activity of EPHX1 in humans is partly attributable to nonsynonymous genetic polymorphisms (that result in amino acid substitutions) in exon 3 (Tyr₁₁₃His, rs1051740) and exon 4 (His₁₃₉Arg, rs2234922; ref. 10). Invitro, EPHX1 activity is reduced (about 40%) associated with ₁₁₃His and increased (about 25%) associated with ₁₃₉Arg, probably due to altered protein stability (11). Furthermore, predicted high epoxide hydrolase activity, based on combined EPHX1 genotypes at codons 113 and 139, isassociated with increased BPDE DNA adducts (12) and chromosomal aberrations (13).

Because of discrepant findings in earlier epidemiologic studies (7, 10, 14-16) of generally smaller sample sizes, we investigated advanced colorectal adenoma risk in relation to the EPHX1 nonsynonymous polymorphisms at codon 113 and 139 among participants in a large screening trial for the early detection of colorectal cancer. As our studies had previously shown that tobacco-related risk for adenoma was largely limited to recent (including current) and heavy smokers (4), we hypothesized that EPHX1-associated risks should be evident primarily in these groups.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
The National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial randomized 77,483 screening arm participants (38,364 men, 39,119 women) and a similar number of nonscreened controls, ages 55 to 74, at 10 US screening centers (Birmingham, AL, Denver, CO, Detroit, MI, Honolulu, HI, Marshfield, WI, Minneapolis, MN, Pittsburgh, PA, Salt Lake City, UT, St.Louis, MO, and Washington, DC; ref. 17). Eligible subjects reported no prior personal history of prostate, lung, colorectal or ovarian cancer. Criteria for exclusion included (a) current treatment for cancer (excluding basal cell and squamous cell skin cancer), (b) prior total colectomy, pneumonectomy, prostatectomy, or bilateral oophorectomy (with bilateral oophorectomy dropped as an exclusion criterion beginning in 1996), (c) participation in another cancer screening or primary prevention study, and (d) recent usage of finasteride (Proscar) or tamoxifen (Nolvadex). Beginning in April 1995, PLCO excluded men reporting more than one prostate-specific antigen blood test, and men and women reporting any lower gastrointestinal procedure (proctoscopy, sigmoidoscopy, barium enema, or colonoscopy) within 3 years before study enrollment. The primary method for recruiting study subjects involved mailing informational brochures and letters of invitation to age-eligible persons identified on public, commercial, or screening center–specific mailing lists.

Physician and nonphysician examiners, all centrally registered, followed standardized procedures to perform and record results from an initial 60-cm flexible sigmoidoscopy examination, done as soon as possible after study entry. As a general rule, PLCO examiners, at the time of the screening examination, did not biopsy or remove polyps or masses. Rather, PLCO referred subjects with screen-detected abnormalities to personal physicians for diagnostic follow-up. PLCO abstracted medical records pertaining to subsequent diagnostic work-ups. Information abstracted from medical records included the occurrence and date of follow-up flexible sigmoidoscopy and/or colonoscopy examinations, the anatomic location, size (visual estimate as recorded on clinical endoscopy reports), histology of polyps and masses observed on follow-up, dates of diagnosis, and tumor-node-metastasis clinical and pathologic stages for subjects with invasive colorectal cancers. Questionnaire data and biological samples were acquired from study participants (18). Participants provided written informed consent. The study was approved by the institutional review boards of the National Cancer Institute and the 10 screening centers.

Study Population
Cases and controls for this study of EPHX1, tobacco use, and adenoma risk were drawn from screening-arm participants at the 10 screening centers of the PLCO Trial who filled out risk factor questionnaires had a successful sigmoidoscopy (insertion to at least 50 cm with >90% of mucosa visible or a suspect lesion identified), and provided a blood sample for use in etiologic studies (Sep. 93-Sep. 99 applied all the conditions described), (n = 42,037; ref. 19). Of these participants, we excluded 4,834 with a self-reported history of ulcerative colitis, Crohn's disease, familial polyposis, colorectal polyps, Gardner's syndrome, or cancer (except basal cell and squamons cell skin cancer). We randomly selected 772 of 1,234 cases with at least one advanced colorectal adenoma (adenoma 1 cm or containing high-grade dysplasia or villous, including tubulovillous, elements) in the distal colon (descending colon and sigmoid or rectum), and 777 of 26,651 control participants, with a negative sigmoidoscopy screening (i.e., no polyp or other suspect lesion), frequency-matched to the cases by gender and ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, and others). Study subjects were predominantly non-Hispanic Whites (94%). Among the 772 cases, 572 (74%) had a lesion 1 cm, 489 (63%) showed advanced histologic features, and 245 (32%) had multiple adenoma. Also, 631 (82%) cases had an advanced adenoma of the descending colon or sigmoid and 232 (30%) had an advanced adenoma of the rectum, including subjects having lesions at both sites.

Genotype Assay
DNA samples were obtained from stored blood samples using Qiagen standard protocols (QIAamp DNA Blood Midi or Maxi kit: http://www1.qiagen.com/default.aspx). Genotyping was conducted by TaqMan (Applied Biosystems, Foster City, CA). All assays were validated and optimized at the NCI Core Genotyping Facility Laboratory http://snp500cancer.nci.nih.gov). Internal laboratory quality controls were Coriell DNA samples containing homozygous major allele, heterozygous, and homozygous minor allele genotypes for each polymorphism under study with four of each control type and four no template controls in every 384 samples. For external blinded quality controls, we interspersed 10% repeated quality control samples from 40 individuals. The blinded samples showed >99% interassay concordance for both assays. Genotype data were successfully obtained for 92% to 93% of study subjects excluding individuals with insufficient DNA (1%), genotyping failures (5-6%), and fingerprint profile review showing subject-specific ambiguities (1%).

Questionnaire Data
Participants completed a baseline general risk factor questionnaire and a 137-item food frequency questionnaire, to report the use of tobacco, alcohol, selected drugs and hormones, body size, and usual dietary intake over the 12 months prior to enrollment. Detailed information on smoking history was collected, including ages started and stopped, total years of use, amount usually used, and type of tobacco used (cigarettes, pipes, and cigars). Subjects who did not smoke cigarettes for more than 6 months or did not smoke pipes or cigars for more than a year were considered to be nonsmokers. For evaluation of risks in relation to time period of cigarette use, cigarette users were classified as long-term quitters (quit 10 years before enrollment) and current or recent smokers (quit <10 years before enrollment). Dietary nutrient intake was calculated by multiplying the reported frequency of consumption for relevant food items by gender- and nutrient-specific portion sizes (20) using the nutrient database from the U.S. Department of Agriculture (21). Dietary intake of benzo(a)pyrene was calculated using a database developed by Kazerouni et al. (22).

Statistical Analysis
Similar to previous studies (7, 23, 24), we inferred that alleles associated with more stable protein sequences (i.e., ₁₁₃Tyr and ₁₃₉Arg) predicted higher total activity of EPHX1. A combined genotype score was derived from the codon 113 and 139 polymorphisms of EPHX1 by calculating the total number of putative high-activity alleles (₁₁₃Tyr and ₁₃₉Arg). Subjects were characterized as having low, medium, or high predicted activities, respectively, depending on whether they carried no or one, two, or three to four copies of the putative high-activity alleles.

Departure from Hardy-Weinberg equilibrium was assessed by comparing the expected to observed genotype frequencies using the asymptotic Pearson's ² test. Odds ratios (OR) and 95% confidence intervals (CI) were obtained using unconditional logistic regression, adjusting for gender, race (non-Hispanic White, non-Hispanic Black, and others), and age (55-59, 60-64, 65-69, and 70-74). We did trend tests for the three-level combined genotype variable using logistic regression models based on the integer score (0, 1, 2). Statistical significance of multiplicative interaction between EPHX1 genotype and smoking was tested using the Wald test for the interaction term in the logistic regression models.

Based on a novel extension of polytomous logistic regression for multivariate outcome analysis (25), we studied whether the effect of EPHX1 alleles varied for three characteristics of adenomas: size (1 versus <1 cm), multiplicity (multiple versus single), and advanced histologic features (high-grade dysplasia or villous versus absence of these features), estimating case to case ORs for each characteristic after controlling for the other two characteristics. Adenoma risks associated with haplotypes defined by multiple polymorphisms were assessed by the SNPEM program (26, 27), using an expectation-maximization algorithm to estimate haplotype frequencies and permutation tests to evaluate differences between cases and controls. All P values were two-sided. Individuals with missing values were excluded from specific analyses.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Distributions of the matching factors of gender and race were similar for cases and controls, however, cases tended to have a higher body mass index, and were older, more likely to have reported a first-degree family history of colorectal cancer, and have had less education (Table 1). Cigarette smoking was associated with increased risk for advanced adenoma (OR, 1.4; 95% CI, 1.2-1.8; Table 2), with greater risks among current and recent cigarette smokers (OR, 2.4; 95% CI, 1.8-3.2). Risks by usual amount smoked were OR, 1.3 (95% CI, 1.0-1.6) for 20 cigarettes per day and OR, 1.7 (95% CI, 1.3-2.2) for >20 cigarettes per day.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
In our study of 772 cases and 777 controls, we found that risks for advanced colorectal adenoma tended to be greatest among carriers of two nonsynonymous variants in EPHX1 (₁₁₃Tyr and ₁₃₉Arg) related to high predicted enzymatic activity, particularly among current and recent smokers. Haplotype analysis showed the strongest risks associated with carriage of two at-risk alleles on the same chromosome, pointing to potential cis effects of the two variants.

Our findings are in close agreement with reports by Cortessis et al. (7) of 464 sigmoidoscopy-identified adenoma cases and 510 matched controls, showing a >4-fold increase in adenoma risk in current smokers with high predicted activity of EPHX1, and by Tiemersma et al. (15) of 385 endoscopy-identified adenoma cases and 396 polyp-free controls, showing a 2-fold risk among current smokers carrying the EPHX1 putative high-activity alleles. Sachse et al. (16), in 490 colorectal cancer patients and 593 controls, found comparable increased risks for colorectal cancer associated with the EPHX1₁₁₃Tyr high-activity variant, but did not take tobacco use into account. In contrast, a study by Ulrich et al. (10), in 530 adenoma and 649 polyp-free controls at colonoscopy, found a protective effect associated with the putative high–activity EPHX1 genotypes among heavy smokers. Also, Harrison et al. (14) in 101 colon cancer patients and 203 controls, found reduced risks associated with the EPHX1₁₁₃ residue predicting high enzymatic activity and no effect associated with the EPHX1₁₃₉ variant.

Reasons for the discrepancy in results are unclear. Neither study of cancer (14, 16) considered interrelationships with tobacco use. Ours was the only study to report specifically on advanced adenoma. Our study and the study by Cortessis et al. (7) were carried out in early detection programs and focused on the distal (left-sided) colon, within reach of a sigmoidoscope, whereas Ulrich et al. (10) studied adenomas in colonoscopy patients and Tiemersma et al. (15) included sigmoidoscopy and colonoscopy-identified subjects. The studies by Ulrich et al. (10) and Tiemersma et al. (15) were carried out in gastroenterology practices, including subjects with right-sided adenomas. Differences in study subject inclusion patterns in screening programs versus gastroenterology practices and differences in the genetic determinants of left-sided versus right-sided adenoma (28, 29) could have contributed to observed risk differentials. Also, our genotyping approach accounted for a closely associated synonymous nucleotide substitution, G₁₁₉A (Lys₁₁₉), which could interfere with the genotyping of Tyr₁₁₃His, causing the heterozygotes to be misclassified as ₁₁₃His homozygotes (30), affecting 3% of the subjects in our early assay development (data not shown). It remains unlikely, however, that these methodologic considerations could completely account for the discrepant results across studies.

Overall results from these reports, including our large investigation, favor the hypothesis that high epoxide hydrolase activity is related to increased risk of colon tumors among cigarette smokers, although further investigation is needed to fully assess this result. High predicted activity of EPHX1 also has been associated in some studies with increased risk of lung cancer (31) and other malignancies (32-34), suggesting that these gene variants may have a broader role in human carcinogenesis.

In our data, meat and dietary PAH intake did not modify adenoma risk associated with EPHX1 genotypes. Cortessis etal. (7) found that high predicted activity of EPHX1 was associated with increased adenoma risk in individuals who regularly ate well-done meat, whereas Ulrich et al. (10) reported elevated adenoma risks associated with low predicted activity in those with high intake of cooked meat. Diet-EPHX1 relationships are more difficult to interpret than smoking-EPHX1 relationships; reporting on diet is less accurate (10) and PAH doses in diet are typically lower and more poorly correlated with PAH biomarkers (9, 35).

EPHX1 has a broad tissue distribution and substrate specificity (36). The coding region substitutions we studied appear to influence enzymatic activity through alteration of protein stability (11) rather than enzyme kinetics (11, 36), and may account for only a fraction of all variation in human EPHX1 activity (37, 38). Additional genetic variants, possibly in regulatory regions of the EPHX1 gene, and variation in transcriptional and posttranscriptional modification may also play a role (36, 37). Investigation of other polymorphic variants in EPHX1 (38, 39), particularly those in the 5'-flanking promoter region, the broader evaluation of haplotypes in the gene region, and further evaluation of gene-variant functional significance may provide a more complete picture of EPHX1-associated risks for colorectal tumors.

The conversion of benzo(a)pyrene to reactive products depends on a cascade of biotransformations, including oxidation by CYP1A1 to the active benzo(a)pyrene 7,8-epoxide, hydration by EPHX1 to the less toxic benzo (apyren 7,8 diol, followed by oxidation through a P450-dependent mechanism to the highly carcinogenic BPDE, detoxification of benzo(a)pyrene and BPDE by glutathione S-transferases, and detoxification by NQO1 of quinones derived from benzo(a) pyrene 7,8 diol through aldo-keto reductase (12, 40). We are expanding our investigations to evaluate tobacco use–associated risks involving polymorphic variants in these genes (41, 42)

In summary, our analysis shows that two nonsynonymous microsomal epoxide hydrolase variants (₁₁₃Tyr and ₁₃₉Arg) are associated with increased risk of advanced colorectal adenoma, particularly among current and recent smokers, implicating this gene and PAHs in tobacco-associated colorectal carcinogenesis.

	Acknowledgments

 
We thank Drs. John K. Gohagan and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center Investigators and staff of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Drs. Rashmi Sinha and Nat Rothman, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Tom Riley and staff, Information Management Services, Inc., Barbara O'Brien and staff, Westat, Inc., and Drs. Bill Kopp, Wen Shao, and staff, Science Applications International Corporation-Frederick for their contributions to making this study possible.

	Footnotes

 
Grant support: Fully funded by the National Cancer Institute, NIH, Department of Health and Human Services

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be here by marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/22/04; revised 7/22/04; accepted 8/ 6/04.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002;31:925–43.[Medline]
2. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999;91:916–32.[Abstract/Free Full Text]
3. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658–62.[Abstract]
4. Ji B-T, Weissfeld JL, Chow W-H, Schoen R, Hayes RB. Tobacco smoking and colorectal hyperplastic and adenomatous polyps. AACR 94th Annual Meeting Proceedings 2003;44:302.
5. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001;10:725–31.[Abstract/Free Full Text]
6. Oesch F. Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica 1973;3:305–40.[Medline]
7. Cortessis V, Siegmund K, Chen Q, et al. A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res 2001;61:2381–5.[Abstract/Free Full Text]
8. Sims P, Grover PL, Swaisland A, Pal K, Hewer A. Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide. Nature 1974;252:326–8.[CrossRef][Medline]
9. Scherer G, Frank S, Riedel K, Meger-Kossien I, Renner T. Biomonitoring of exposure to polycyclic aromatic hydrocarbons of nonoccupationally exposed persons. Cancer Epidemiol Biomarkers Prev 2000;9:373–80.[Abstract/Free Full Text]
10. Ulrich CM, Bigler J, Whitton JA, Bostick R, Fosdick L, Potter JD. Epoxide hydrolase Tyr113His polymorphism is associated with elevated risk of colorectal polyps in the presence of smoking and high meat intake. Cancer Epidemiol Biomarkers Prev 2001;10:875–82.[Abstract/Free Full Text]
11. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994;3:421–8.[Abstract/Free Full Text]
12. Pastorelli R, Guanci M, Cerri A, et al. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide. Cancer Epidemiol Biomarkers Prev 1998;7:703–9.[Abstract]
13. Cajas-Salazar N, Au WW, Zwischenberger JB, et al. Effect of epoxide hydrolase polymorphisms on chromosome aberrations and risk for lung cancer. Cancer Genet Cytogenet 2003;145:97–102.[CrossRef][Medline]
14. Harrison DJ, Hubbard AL, MacMillan J, Wyllie AH, Smith CA. Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br J Cancer 1999;79:168–71.[CrossRef][Medline]
15. Tiemersma EW, Kloosterman J, Bunschoten A, Kok FJ, Kampman E. Role of EPHX genotype in the associations of smoking and diet with colorectal adenomas. IARC Sci Publ 2002;156:491–3.[Medline]
16. Sachse C, Smith G, Wilkie MJ, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 2002;23:1839–49.[Abstract/Free Full Text]
17. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000;21:251–72S.
18. Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:349–55S.
19. Peters U, Hayes RB, Chatterjee N, et al. Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2004;13:546–52.[Abstract/Free Full Text]
20. Subar AF, Midthune D, Kulldorff M, et al. Evaluation of alternative approaches to assign nutrient values to food groups in food frequency questionnaires. Am J Epidemiol 2000;152:279–86.[Abstract/Free Full Text]
21. Tippett KS, Cypel YS. Design and operation: the continuing survey of food intakes by individuals and the diet and health knowledge survey, 1994-96. In: Continuing Survey of Food Intakes by Individuals 1994-96, Nationwide Food Surveys Rep. No. 96-1. 1998. U.S. Department of Agriculture, Agricultural Research Service.
22. Kazerouni N, Sinha R, Hsu CH, Greenberg A, Rothman N. Analysis of 200 food items for benzoapyrene and estimation of its intake in an epidemiologic study. Food Chem Toxicol 2001;39:423–36.[CrossRef][Medline]
23. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res 2000;60:534–6.[Abstract/Free Full Text]
24. Zhao H, Spitz MR, Gwyn KM, Wu X. Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. Mol Carcinog 2002;33:99–104.[CrossRef][Medline]
25. Chatterjee N. A two-stage regression model for epidemiologic studies with multivariate disease classification data. J Am Stat Assoc 2004;99(465):127–38.
26. Fallin D, Schork NJ. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 2000;67:947–59.[CrossRef][Medline]
27. Fallin D, Cohen A, Essioux L, et al. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res 2001;11:143–51.[Abstract/Free Full Text]
28. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779–88.
29. Glebov OK, Rodriguez LM, Nakahara K, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 2003;12:755–62.[Abstract/Free Full Text]
30. Keicho N, Emi M, Kajita M, et al. Overestimated frequency of a possible emphysema-susceptibility allele when microsomal epoxide hydrolase is genotyped by the conventional polymerase chain reaction-based method. J Hum Genet 2001;46:96–8.[CrossRef][Medline]
31. Lee WJ, Brennan P, Boffetta P, et al. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers 2002;7:230–41.[CrossRef][Medline]
32. Lancaster JM, Brownlee HA, Bell DA, et al. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog 1996;17:160–2.[CrossRef][Medline]
33. Park JY, Schantz SP, Lazarus P. Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype. Oral Oncol 2003;39:483–90.[CrossRef][Medline]
34. Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX. CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: study of population from a high-incidence area in north China. World J Gastroenterol 2003;9:1394–7.[Medline]
35. Van Rooij JG, Veeger MM, Bodelier-Bade MM, Scheepers PT, Jongeneelen FJ. Smoking and dietary intake of polycyclic aromatic hydrocarbons as sources of interindividual variability in the baseline excretion of 1-hydroxypyrene in urine. Int Arch Occup Environ Health 1994;66:55–65.[CrossRef][Medline]
36. Omiecinski CJ, Hassett C, Hosagrahara V. Epoxide hydrolase-polymorphism and role in toxicology. Toxicol Lett 2000;112–113:365–70.[CrossRef]
37. Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys 1997;337:275–83.[CrossRef][Medline]
38. Raaka S, Hassett C, Omiencinski CJ. Human microsomal epoxide hydrolase: 5'-flanking region genetic polymorphisms. Carcinogenesis 1998;19:387–93.[Abstract/Free Full Text]
39. Saito S, Iida A, Sekine A, Eguchi C, Miura Y, Nakamura Y. Seventy genetic variations in human microsomal and soluble epoxide hydrolase genes (EPHX1 and EPHX2) in the Japanese population. J Hum Genet 2001;46:325–9.[CrossRef][Medline]
40. Palackal NT, Lee SH, Harvey RG, Blair IA, Penning TM. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J Biol Chem 2002;277:24799–808.[Abstract/Free Full Text]
41. Hou L, Huang WY, Weissfeld J, Gohagan J, Hayes RB. CYP1A1 (I462V) and NQO1 (P187S) polymorphisms and colorectal adenoma abstract. Ann Epidemiol 2003;13:564.
42. Moore L, Dean M, Huang W-Y, Hayes RB. Risk of advanced adenoma associated with GSTM1, GTST1 and GSTP1 genotypes and cigarette smoking in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial abstract. 2003 AACR Conference on Molecular and Genetic Epidemiology of Cancer, B62.2003.

This article has been cited by other articles:

				J. Russo, G. A. Balogh, I. H. Russo, and and the Fox Chase Cancer Center Hospital Network P Full-term Pregnancy Induces a Specific Genomic Signature in the Human Breast Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 51 - 66. [Abstract] [Full Text] [PDF]

				P. N. Mitrou, M. A. Watson, A. S. Loktionov, C. Cardwell, M. J. Gunter, W. S. Atkin, C. P. Macklin, T. Cecil, D.T. Bishop, J. Primrose, et al. Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from the UKFSS Study Carcinogenesis, April 1, 2007; 28(4): 875 - 882. [Abstract] [Full Text] [PDF]

				E. L. Goode, J. D. Potter, W. R. Bamlet, D. N. Rider, and J. Bigler Inherited variation in carcinogen-metabolizing enzymes and risk of colorectal polyps Carcinogenesis, February 1, 2007; 28(2): 328 - 341. [Abstract] [Full Text] [PDF]

				B.-T. Ji, J. L. Weissfeld, W.-H. Chow, W.-Y. Huang, R. E. Schoen, R. B. Hayes, and for the Prostate, Lung, Colorectal, and Ovarian Tr Tobacco smoking and colorectal hyperplastic and adenomatous polyps. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 897 - 901. [Abstract] [Full Text] [PDF]

				J. Brogger, V. M. Steen, H. G. Eiken, A. Gulsvik, and P. Bakke Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. Eur. Respir. J., April 1, 2006; 27(4): 682 - 688. [Abstract] [Full Text] [PDF]

				N. L. Nock, X. Liu, M. S. Cicek, L. Li, F. Macarie, B. A. Rybicki, S. J. Plummer, G. T. MacLennan, G. Casey, and J. S. Witte Polymorphisms in polycyclic aromatic hydrocarbon metabolism and conjugation genes, interactions with smoking and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 756 - 761. [Abstract] [Full Text] [PDF]

				W.-Y. Huang, S. I. Berndt, D. Kang, N. Chatterjee, S. J. Chanock, M. Yeager, R. Welch, R. S. Bresalier, J. L. Weissfeld, and R. B. Hayes Nucleotide Excision Repair Gene Polymorphisms and Risk of Advanced Colorectal Adenoma: XPC Polymorphisms Modify Smoking-Related Risk. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 306 - 311. [Abstract] [Full Text] [PDF]

				L. E. Moore, W.-Y. Huang, N. Chatterjee, M. Gunter, S. Chanock, M. Yeager, B. Welch, P. Pinsky, J. Weissfeld, and R. B. Hayes GSTM1, GSTT1, and GSTP1 Polymorphisms and Risk of Advanced Colorectal Adenoma Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1823 - 1827. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, W.-Y. Articles by Hayes, R. B. Search for Related Content PubMed PubMed Citation Articles by Huang, W.-Y. Articles by Hayes, R. B.